Joanne M. Donovan Form 3 CATABASIS PHARMACEUTICALS / Joanne M. Donovan ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Donovan Joanne M.

(Last) (First) (Middle)

C/O CATABASIS PHARMACEUTICALS, INC. ONE

KENDALL SQUARE BLDG. 1400E, SUITE B14202

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/24/2015

3. Issuer Name and Ticker or Trading Symbol
CATABASIS PHARMACEUTICALS INC [ CATB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(1)	(1)	Common Stock	409	(1)	D
Stock Option (right to buy)	(2)	09/06/2021	Common Stock	27,237(3)	1.93(3)	D
Stock Option (right to buy)	(4)	12/17/2022	Common Stock	7,204(3)	2.31(3)	D
Stock Option (right to buy)	(5)	12/17/2022	Common Stock	10,496(3)	2.31(3)	D
Stock Option (right to buy)	(6)	12/17/2022	Common Stock	24,584(3)	2.31(3)	D
Stock Option (right to buy)	(7)	04/16/2023	Common Stock	14,305(3)	2.31(3)	D
Stock Option (right to buy)	(8)	03/18/2024	Common Stock	25,291(3)	6.81(3)	D
Stock Option (right to buy)	(9)	03/25/2025	Common Stock	4,669(3)	11.05(3)	D

Explanation of Responses:

1. The Series B Preferred Stock is convertible into Common Stock on a 1-for-12.85 basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

2. This option was granted on September 7, 2011 and vested as to 25% of the shares on July 14, 2012 with the remaining 75% of the shares vesting in equal monthly installments thereafter through July 14, 2015.

3. Reflects a 1-for-12.85 reverse stock split effected on June 11, 2015.

4. This option was granted on December 18, 2012 and vested as to 25% of the shares on December 1, 2012 with the remaining 75% of the shares vesting in equal monthly installments thereafter through December 1, 2015.

5. This option was granted on December 18, 2012 and vested as to 25% of the shares on July 10, 2013 with the remaining 75% of the shares vesting in equal monthly installments thereafter through July 10, 2016.

6. This option was granted on December 18, 2012 and vested as to 25% of the shares on January 1, 2014 with the remaining 75% of the shares vesting in equal monthly installments thereafter through January 1, 2017.

7. This option was granted on April 17, 2013 and vested as to 25% of the shares on January 18, 2014 with the remaining 75% of the shares vesting in equal monthly installments thereafter through January 18, 2017.

8. This option was granted on March 19, 2014 and vested as to 25% of the shares on January 1, 2015 with the remaining 75% of the shares vesting in equal monthly installments thereafter through January 1, 2018.

9. This option was granted on March 26, 2015 and vests over four years with 25% of the shares vesting on March 26, 2016, and the remaining 75% of the shares vesting in equal monthly installments thereafter through March 26, 2019.

Remarks:

Exhibit Index: 24.1 Power of Attorney

	/s/ Joanne M. Donovan	06/24/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.